Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUV-161 in Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization
NCT07397468Phase 2Recruiting
- Sponsor
- Juvena Therapeutics
- Start
- Feb 2026
- Primary completion
- Jul 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JUV-161 in muscle atrophy (3 arms), sponsored by Juvena Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events at Day 96, Change in Quadriceps Muscle Mass and Volume at Day 45 and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
JUV-161
03
Conditions
muscle atrophy
Beyond the preview
Go deeper on NCT07397468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07397468.